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Abstract
Introduction: SHP656 is the first factor VIII (FVIII) product developed using polysia-
lylation (PSA) technology, in which full-length recombinant (r) FVIII (anti-haemophilic 
factor [recombinant]) is conjugated with a 20 kDa PSA polymer.
Aim: To compare the safety, immunogenicity and pharmacokinetics of SHP656 vs 
the parent rFVIII (octocog alfa) after single infusions of 25-75 IU/kg in patients with 
severe haemophilia A (FVIII activity <1%).
Methods: Multinational, phase 1, prospective, open-label, two-period, fixed-se-
quence, dose-escalation trial (clinicaltrials.gov NCT02716194). Patients received 
single doses of rFVIII and then SHP656 sequentially at the same dose: 25 ± 3 IU/kg 
(Cohort 1), 50 ± 5 IU/kg (Cohort 2) and 75 ± 5 IU/kg (Cohort 3).
Results: Forty patients received rFVIII: 11 in Cohort 1, 16 in Cohort 2 and 13 in 
Cohort 3. Two patients withdrew before receiving SHP656, leaving 38 patients who 
completed the study and received both treatments. No treatment-related adverse 
events (AEs), serious AEs, deaths, study withdrawals, thrombotic events or allergic 
reactions were reported; and no significant treatment-related changes in laboratory 
parameters or vital signs. No patients developed FVIII inhibitors or antibodies to 
PSA. FVIII activity was significantly prolonged following SHP656 administration vs 
rFVIII with an approximately 1.5-fold extension in mean residence time (P < .05). 
Exposure increased proportional to the SHP656 dose over the 25-75 IU/kg dose 
range.
Conclusion: Polysialylation of rFVIII confers a half-life extension similar to that of 
approved extended half-life products that use either PEGylation or Fc fusion technol-
ogy and was not associated with any treatment-related adverse events.
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1  | INTRODUC TION
Haemophilia A is an inherited disorder characterized by a deficiency 
of functional factor VIII (FVIII) leading to uncontrolled bleeding.1 
Patients with severe haemophilia A (FVIII activity levels <1%) may 
experience frequent spontaneous bleeds into joints that can lead 
to serious arthropathy.1 The goal of therapy for many patients is to 
avoid bleeding episodes and thereby preserve joints using regular 
(prophylactic) intravenous infusions of exogenous FVIII.2 During 
prophylaxis, the time spent at a FVIII activity level of <1% was cor-
related with the annual bleeding rate.3 Therefore, the goal of pro-
phylaxis is to maintain FVIII activity levels greater than at least 1%.4
Traditional FVIII products typically require infusions three times 
weekly or every other day5; newer preparations with extended half-
lives may permit less frequent infusion and therefore benefit patients 
and caregivers. Manufacturers have investigated several mechanisms 
to extend FVIII activity half-life in vivo, including the use of Fc fusion 
protein6,7 and PEGylation (PEG).8-11 These approaches have resulted 
in approximately 1.4 to 1.5-fold extensions in half-life,12 making twice-
weekly prophylactic dosing a realistic option for many patients, as seen 
with ADYNOVATE® (rurioctocog alfa pegol; ADYNOVI™, Baxalta US 
Inc, a Takeda company)10 and ELOCTATE® (Fc-rFVIII; Antihemophilic 
Factor [Recombinant], Fc Fusion Protein, Bioverativ Therapeutics).7 
However, there remains a need for a FVIII product with more conve-
nient dosing (such as once weekly or less frequent), which could im-
prove the adherence to treatment in this patient population.13
To address this need, we investigated another approach to the 
extension of FVIII half-life using polysialylation. Polysialic acids (PSAs) 
have been successfully utilized in other therapeutic areas to prolong 
half-life, improve stability and reduce renal excretion.14,15 SHP656 
(Baxalta US Inc, a Takeda company), formerly known as BAX 826, is the 
first FVIII product to be developed using polysialylation technology, in 
which full-length recombinant FVIII (rFVIII) (octocog alfa; anti-haemo-
philic factor [recombinant]; ADVATE®, Baxalta US Inc, a Takeda com-
pany) is conjugated with a 20 kDa PSA polymer, using polysialylation 
methods developed in conjunction with Xenetic Biosciences, Inc. In 
preclinical studies, the new compound achieved 2-3-fold greater exten-
sion of mean residence time (MRT) than the parent compound, rFVIII.16
Based on these promising pharmacokinetic (PK) characteristics, 
and evidence of a potentially improved immunogenicity profile of 
SHP656 compared to ADYNOVATE,17 we conducted this first-in-hu-
man study evaluating the safety, tolerability and PKs of SHP656 in 
patients with severe haemophilia A.
2  | METHODS
This study was performed in accordance with Good Clinical Practice 
and ethical principles consistent with the Declaration of Helsinki 
and was registered at ClinicalTrials.gov (NCT02716194). The study 
protocol, consent forms and all amendments were approved by all 
relevant ethics committees, and written informed consent was ob-
tained from all patients prior to enrolment.
2.1 | Patient population
The study enrolled adult males (aged 18-65 years) with severe 
haemophilia (FVIII activity <1% at prior diagnosis or confirmed at 
screening). Patients were previously treated with FVIII concentrates 
for ≥150 exposure days; human immunodeficiency virus-negative, or 
with stable disease and CD4 + cell counts ≥200 cells/mm3; and hep-
atitis C virus-negative, or positive with chronic stable disease as as-
sessed by the investigator, and had Karnofsky Performance18 scores 
≥60. Potential patients were excluded if they had detectable FVIII 
inhibitors (titre ≥0.6 Bethesda units [BU] by Nijmegen-Bethesda 
assay19 performed by a central laboratory at screening) or a his-
tory of FVIII inhibitors at any time with a titre ≥0.4 BU (Nijmegen-
Bethesda assay) or ≥0.6 BU (Bethesda assay).20 Exclusion criteria 
also included severe chronic renal (serum creatinine >2.0 mg/dL) or 
hepatic impairment (alanine aminotransferase ≥5 × the upper limit 
of normal or international normalized ratio >1.5) and the presence of 
any other inherited or acquired bleeding disorder.
2.2 | Study design
This was a multinational, phase 1, prospective, open-label, two-period, 
fixed-sequence, dose-escalation trial to evaluate the safety and PK 
of SHP656 compared with unmodified rFVIII in patients with severe 
haemophilia A (FVIII activity <1%). The study was conducted at 20 
sites in the European Union and Russia. Patients underwent a 30-day 
screening period followed by a minimum 4-day washout, after which 
they were divided into three cohorts (Figure 1). Cohort 1 received a 
single dose of rFVIII (25 ± 3 IU/kg) followed by 3 days of PK sampling. 
Following a minimum 4-day washout, patients then received the same 
dose of SHP656 (25 ± 3 IU/kg) followed by a 7-day PK evaluation. 
SHP656 was administered to the first three patients with a minimum 
24-hour staggered interval to allow in-hospital safety observation 
for 24 hours; subsequent infusions were dependent on confirma-
tion of safety in these three patients. After data from Cohort 1 had 
been reviewed and approved by the funder's internal safety monitor-
ing committee, this sequential dose comparison was repeated with 
single doses of rFVIII and then SHP656 at 50 ± 5 IU/kg in Cohort 2. 
After review of results from Cohort 2, Cohort 3 received 75 ± 5 IU/kg 
rFVIII and then SHP656. For all patients, safety assessments were per-
formed at days −1 (admission), 1, 4, 8, 14 and at 6 weeks post-SHP656 
infusion. Immunogenicity evaluations were carried out at screening, 
prior to infusion during each study period, on day 8 after SHP656 in-
fusion, and at 6 weeks ± 4 days. Patients remained on their standard 
therapy during the screening and follow-up periods (Figure 1).
2.3 | Objectives
The primary objective of the study was to assess the tolerability and 
safety of SHP656 after single infusions of 25 ± 3, 50 ± 5 or 75 ± 5 IU/
kg. Clinical adverse events (AEs), immunogenicity, vital signs and clini-
cal laboratory analyses were recorded up to 6 weeks ± 4 days after 
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infusions. Secondary objectives included comparison of the PK pro-
files of SHP656 with those for equivalent doses of rFVIII and deter-
mination of the PK dose proportionality of SHP656. The influence of 
anti-PSA antibodies on the PK profile of SHP656 was also determined.
2.4 | Analytical methods
Blood samples were drawn for FVIII activity assessments and 
PK evaluation within 30 minutes prior to infusion, and postinfu-
sion at 15 ± 5, 30 ± 5, 60 ± 5 minutes, 3 ± 0.5, 6 ± 0.5, 9 ± 0.5, 
12 ± 0.5, 24 ± 4, 32 ± 4, 48 ± 4, 56 ± 4 and 72 ± 4 hours for both 
rFVIII and SHP656. Additional blood samples for determination 
of SHP656 levels were carried out at 96 ± 6, 120 ± 6, 144 ± 6 and 
168 ± 6 hours.
Factor VIII activity levels were determined using both chromo-
genic assay (HemosIL ELECTRACHROME FVIII, Instrumentation 
Laboratory Company) and one-stage clotting assay (OSCA; ACL 
TOP 500, Instrumentation Laboratory Company) using FVIII-
depleted plasma and activator reagent Pathromtin SL (Siemens). 
Immunogenicity assessments using enzyme-linked immunosorbent 
assay included inhibitory antibodies to FVIII (Nijmegen-Bethesda 
assay); immunoglobulin G (IgG)- and immunoglobulin M (IgM)-
binding antibodies to FVIII and SHP656, IgG and IgM anti-PSA an-
tibodies, total Ig anti-Chinese hamster ovary (CHO) antibodies and 
human anti-mouse antibodies (HAMA).
2.5 | Pharmacokinetic analysis
PK parameters were calculated by standard non-compartmental 
methods using Phoenix® WinNonlin® 6.4 (Pharsight Corp.) and 
preinfusion-corrected data. Predose values greater than the lower 
limit of quantification, regardless of their magnitude, indicated un-
expected endogenous and/or exogenous FVIII activity that had to be 
accounted for in the PK analysis.21 Corresponding adjustments were 
applied on a case-by-case basis taking all available data into account. 
For profiles with apparent endogenous FVIII activity at baseline, 
postdose activity levels were adjusted by subtracting the baseline 
level from all postdose FVIII activity levels.22 For those without an 
apparent endogenous background at baseline, a proportional adjust-
ment23 was used postdose to account for residual FVIII activity from 
a previous infusion. FVIII activity data collected after the occurrence 
of a bleeding episode during a PK assessment period were excluded 
from the PK parameter analysis and were not included in mean PK 
parameter plots. PK parameters of the affected period were also ex-
cluded for statistical analysis.
Actual sampling times, doses and the duration of the infusion 
were used for the calculation of PK parameters, including the 
area under the plasma concentration-time curve (AUC) from time 
0 extrapolated to infinity (AUC0-∞), AUC up to the last quantifi-
able concentration (AUC0-last), AUC from time 0-72 hours (AUC0-
72h) for rFVIII and SHP656, and AUC from time 0-168 hours for 
SHP656 only. Terminal half-life (t½), MRT, maximum plasma con-
centration (Cmax), incremental recovery at Cmax (IR), clearance (CL), 
volume of distribution at steady state (Vss) and minimum time to 
reach Cmax (Tmax) were determined. The dose proportionality of 
SHP656 over the administered dose range was assessed using a 
power law model.
2.6 | Statistical analyses
A sample size of 30 patients was considered sufficient to allow as-
sessment of the tolerability and the safety of SHP656 and to de-
termine the PK profile.24 Statistical analyses were performed using 
SAS® Version 9.4 (SAS Institute, Inc).
As recommended by Brett et al,25 PK parameters AUC0-∞, AUC0-
72h, Cmax, t½, MRT and CL were log-transformed prior to statistical 
evaluation. PK parameters were analysed by cohort for treatment 
F I G U R E  1   Study design. a6 wk ± 4 d post-SHP656 infusion. bFollowed by minimum 4-day (96-h) washout period (maximum 4 wk) prior 
to SHP656 infusion. cBlood samples for PK analysis were collected predose and up to 72 h following rFVIII administration and predose and 
up to 168 h following SHP656 administration. Blood samples for measurement of FVIII activity and FVIII antigen levels were collected at 
screening, during PK study visits, and at termination visit. Patients were to remain at the study site for 12-h postinfusion and return the 
following day for the 24-hour PK sampling. AE, adverse event; FVIII, factor VIII; PK, pharmacokinetic; rFVIII, recombinant human factor VIII
Measure
Visit 1 
Screening
assessments
Visit 2 Visit 3 Visit 4 
(Termination 
visit)
Days
-30 to -2
Day -1 
(admission)
Day 1 Days 2-3 Day 4 Day 1 Days 2-8 Day 14 Day 23
6 weeks 
± 4 daysa
Treatment 
administration
rFVIII
(25, 50, or 
75 IU/Kg)b
SHP656
(25, 50, or 
75 IU/Kg)
PK assessmentc
Immunogenicity 
evaluation  (Predose)  (Predose)  (Day 8)
AE evaluation
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comparison using a linear mixed-effects model with treatment as a 
fixed effect and patient as a random effect. Least-squares (LS) means 
with corresponding 95% confidence intervals (CIs) for the two treat-
ments were determined. The differences in LS means between 
SHP656 and rFVIII and the corresponding 95% CIs were also de-
termined. Back transformation provided the ratios of the geometric 
means and corresponding CIs for the treatment comparisons (SHP656 
vs rFVIII).
The dose proportionality of the PK parameters AUC0-∞, AUC0-
last and Cmax for SHP656, over the administered dose range, was ex-
plored using the following power law model: log (parameter) = a + b 
* log (dose). The power law model parameters were estimated using 
an LS regression method and the 90% CIs were constructed. The in-
crease in PK parameter values in response to a doubling of the dose 
was estimated with corresponding two-sided 90% CIs.26
3  | RESULTS
3.1 | Patient characteristics
Forty-four subjects were enrolled, of which two failed screening 
and two withdrew before administration of the study drug. Forty 
patients received rFVIII; 11 in Cohort 1 (25 ± 3 IU/kg), 16 in Cohort 
2 (50 ± 5 IU/kg) and 13 in Cohort 3 (75 ± 5 IU/kg). Of these, two 
further patients withdrew before receiving SHP656, leaving 38 pa-
tients who completed the study (10, 15 and 13 in Cohorts 1, 2 and 
3, respectively). All 40 patients who received rFVIII were included 
in the safety analysis, and 39 were included in the PK analyses. The 
demographic and clinical characteristics of the patients are summa-
rized in Table 1. Thirty-nine (97.5%) patients were white, the mean 
(±standard deviation [SD]) age of the 40 patients who received 
rFVIII was 35.3 (±10.5) years, and the mean body mass index (BMI) 
was 27.1 (±4.9). Mean age, height and BMI did not differ among 
the three cohorts, but patients in Cohort 3 had slightly lower body 
weights than those in Cohorts 1 and 2 (Table 1).
3.2 | Safety and tolerability
No serious AEs, thrombotic events or allergic reactions were reported 
following rFVIII or SHP656 administration, and no treatment-related 
AEs occurred at any point during the study. A total of 58 non-serious 
AEs occurred during the study; all events were resolved or resolving 
at study completion. No significant treatment-related changes in ei-
ther clinical laboratory values or vital signs were recorded.
3.3 | Immunogenicity
Five patients had positive antibodies at screening; anti-SHP656 IgG 
(n = 1), anti-SHP656 IgM and anti-PSA IgM (n = 1), and anti-PSA IgM 
(n = 3). New anti-FVIII and anti-PSA FVIII IgG antibodies were de-
tected in two of these patients after initiation of SHP656 dosing. 
Both had low (1:40-1:80) unconfirmed titres for these antibodies at 
screening, and it was considered unlikely that they represented de 
Parameter
Cohort 1
rFVIII/SHP656
25 IU/kg
(n = 11)
Cohort 2
rFVIII/SHP656
50 IU/kg
(n = 16)
Cohort 3
rFVIII/SHP656
75 IU/kg
(n = 13)
Race, n (%)
White 10 (90.9) 16 (100) 13 (100)
Other 1 (9.1) 0 0
Ethnicity, n (%)
Hispanic or Latino 1 (9.1) 0 1 (7.7)
Not Hispanic or 
Latino
10 (90.9) 16 (100) 12 (92.3)
Age, y, mean ± SD
(min-max)
36.0 ± 10.6
(20-59)
34.6 ± 9.9
(19-55)
35.5 ± 11.9
(18-63)
Weight, kg, 
mean ± SD
(min-max)
84.6 ± 13.8
(70-118)
86.9 ± 18.3
(59-139)
79.5 ± 12.5
(66-110)
Height, cm, 
mean ± SD
(min-max)
176 ± 6.2
(168-190)
177 ± 8.9
(155-194)
175 ± 5.2
(163-182)
BMI, kg/m2, 
mean ± SD
(min-max)
27.5 ± 5.5
(20-41)
27.6 ± 5.4
(21-41)
26.0 ± 3.7
(22-33)
Abbreviations: BMI, body mass index; max, maximum; min, minimum; rFVIII, recombinant factor 
VIII; SD, standard deviation.
TA B L E  1   Patient characteristics
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novo antibody formation in response to SHP656. No patients devel-
oped antibodies to CHO or HAMA.
Given the low number of patients who had positive antibody re-
sults, the assessment of interactions with PK parameters was limited 
to three patients in Cohort 3 who were positive for anti-PSA antibodies 
at screening. In these three patients, mean (SD) MRT after administra-
tion of SHP656 was shorter compared with those who were anti-PSA 
antibody negative (20.0 [3.8] vs 26.8 [6.3] hours, respectively).
F I G U R E  2   Median (IQR) preinfusion-corrected plasma FVIII activity (linear and semi-logarithmic scales) following infusion of rFVIII and 
SHP656 at (A) 25, (B) 50 and (C) 75 IU/kg. IQR, inter-quartile range; FVIII, factor VIII; rFVIII, recombinant factor VIII
(A) 25 IU/kg
(B) 50 IU/kg
(C) 75 IU/kg
rFVIII (n = 16)
SHP656 (n = 10)
rFVIII (n = 12)
SHP656 (n = 11)
rFVIII (n = 12)
SHP656 (n = 11)
rFVIII (n = 11)
SHP656 (n = 8)
rFVIII (n = 11)
SHP656 (n = 8)
rFVIII (n = 16)
SHP656 (n = 10)
Nominal time (h)
0 12
100
80
60
40
20
0
200
150
100
50
0
0
50
100
150
200
250
300
350
1000
100
10
1
0.1
0.01
1000
100
10
1
1
0.1
0.01
1000
100
10
0.1
0.01
24 36 48 60 72 84 96 108 120 132 144 156 168
Nominal time (h)
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
Nominal time (h)
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
Nominal time (h)
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
Nominal time (h)
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
Nominal time (h)
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
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3.4 | Pharmacokinetics
PK data were evaluable for 39 patients, of which 38 received both 
treatments. There is generally a good agreement between OSCA 
and chromogenic assay results for human plasma FVIII and rFVIII. 
However, for SHP656, preliminary in vitro and in vivo investiga-
tions suggested that OSCA resulted in under-estimation of FVIII 
activity compared with the chromogenic assay (unpublished data). 
Therefore, all PK parameters presented in this paper were calculated 
using the chromogenic assay.
Dose-related increases in preinfusion-corrected FVIII activity 
were observed for both rFVIII and SHP656 (Figure 2). Median preinfu-
sion-corrected FVIII activity rose sharply to a maximum shortly after 
administration of rFVIII and SHP656, and then declined exponentially, 
with a more rapid decline observed for rFVIII, as expected Tmax corre-
sponded with the first sampling time points (Figure 2).
Median observed FVIII activity following SHP656 infusion re-
mained >1% for ≥96 hours in all cohorts, and for 120 hours in the 
75 IU/kg cohort. Consistent with these observations, geometric mean 
AUC0-∞ and AUC0-72 were higher for SHP656 than rFVIII, as were t½ 
and MRT while Cmax and CL were lower (Table 2). The extension of 
MRT with SHP656 compared with rFVIII was approximately 1.5-fold 
for all dose cohorts. These differences were also statistically signifi-
cant (at the 5% level) in all three cohorts indicated by an exploratory 
comparison based on the ratio of geometric means and corresponding 
two-sided 95% CIs. As estimated from the power law model, AUC0-
∞, AUC0-last and Cmax increased proportional to the dose of SHP656 
over the 25-75 IU/kg range evaluated. The estimated increases per 
doubling of dose were 1.98 (90% CI: 1.55-2.53) for AUC0-∞, 2.01 (90% 
CI: 1.56-2.59) for AUC0-last and 2.06 (90% CI: 1.78-2.37) for Cmax. 
Geometric mean estimates for Vss, presented here for completeness, 
were 0.43 dL/kg [geometric coefficient of variation (CV) 21%] for 
rFVIII and 0.46 dL/kg (CV 34%) for SHP656 for all cohorts combined. 
Corresponding estimates for IR were 3.2 IU/dL:IU/kg (CV 18%) and 
2.6 IU/dL:IU/kg (CV 29%) for FVIII and SHP656, respectively.
4  | DISCUSSION
In this single-dose study, there were no treatment-related AEs, seri-
ous AEs, deaths, study withdrawals, thrombotic events or allergic 
reactions, and no significant treatment-related changes in labora-
tory parameters or vital signs associated with SHP656. No patients 
developed de novo FVIII inhibitors or antibodies to PSA during the 
study. FVIII activity was significantly prolonged following SHP656 
administration compared with rFVIII, with an approximately 1.5-fold 
extension based on MRT and 1.3- to 1.4-fold extension based on 
t½. Exposure also appeared to increase proportional to the dose of 
SHP656 over the 25-75 IU/kg range.
Polysialylation prolonged the t½ of FVIII activity to a sim-
ilar degree to that shown for marketed extended half-life prod-
ucts utilizing either PEG (rurioctocog alfa pegol; ADYNOVATE®, 
ADYNOVI™); or Fc fusion protein technology (Fc-rFVIII; ELOCTATE 
[Antihemophilic Factor [Recombinant], Fc Fusion Protein]).12 The 
results for MRT, which adequately measures the overall per-
sistence of the drug in the body,27 indicated an approximately 1.5-
fold prolonged FVIII activity with SHP656 compared with rFVIII 
across all dose levels. The differences in MRT were statistically 
significant (at the 5% level) in all three cohorts. Supplemental anal-
yses indicated that a SHP656 dose of 75 IU/kg administered every 
5 days may maintain a FVIII activity trough level of 1% for the ma-
jority of patients. When dosed once weekly, substantially higher 
doses than those used in routine prophylaxis (ie 20-80 IU/kg4) are 
expected to be necessary.
It has been hypothesized that clearance of modified rFVIII vari-
ants is largely regulated by interaction with von Willebrand factor 
(VWF), and longer-acting FVIII variants may require modifications 
that exclude association with endogenous VWF.28 The in vitro and 
in vivo data had suggested that, besides other possible mechanisms, 
the prolonged half-life of PSA-rFVIII could be attributed to two 
possibly intertwined mechanisms: reduced binding to scavenger re-
ceptors (ie LRP1) and a largely VWF interaction-independent circu-
lation time.17 The improved PK behaviour of PSA-rFVIII compared 
with rFVIII in preclinical animal models appears to be translated to 
humans given the observed half-life extending effect of rFVIII poly-
sialylation. In this study, while polysialylation prolonged the half-
life of FVIII activity, it was to a similar degree to that shown for 
marketed extended half-life products. A small number of patients 
had pre-existing PSA antibodies at screening. In the highest dose 
cohort (75 IU/kg), there were three such individuals, and mean FVIII 
activity was lower in these patients compared with those without 
anti-PSA antibodies.
The safety profile of SHP656 in this study of 40 patients, with 
no treatment-related AEs or significant laboratory findings or vital 
signs, appears to be at least equivalent to the profiles of rFVIII or 
marketed extended half-life FVIII compounds. In the pivotal study 
of PEG-rFVIII, six out of 137 (4.4%) patients reported seven AEs 
that were considered possibly related to the product, all of which 
were non-serious and consistent with the known safety profile of 
the parent compound rFVIII.10 Similarly, only 10 out of 164 (6.1%) 
patients in the phase 3 study of Fc-rFVIII experienced AEs related 
to the investigational product; none was serious.7 While the de novo 
antibody formation in response to SHP656 was not a concern in this 
study, a multiple-dose study with a longer follow-up would be re-
quired to better understand the immunogenicity profile of SHP656.
5  | CONCLUSION
The results from this single-dose study indicate that polysialylation 
of rFVIII confers a half-life extension similar to that of approved ex-
tended half-life products that use either PEG or Fc fusion technol-
ogy and was not associated with any treatment-emergent adverse 
events.
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